Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
1.
Z Geburtshilfe Neonatol ; 220(3): 95-105, 2016 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-27315397

RESUMO

Venous thromboembolism (VTE) is one of the leading causes of maternal deaths worldwide. Due to the increasing number of pregnant women with risk factors, the incidence of VTE has risen over the past decades. Mortality and morbidity of VTE are potentially preventable, since more than two-thirds of these women have identifiable risk factors and may benefit from appropriate thromboprophylaxis. The cornerstones for prevention of VTE are the individual and careful assessment of preexisting and new-onset/transient risk factors during pregnancy as well as before and after delivery and a risk-stratified pharmacological thromboprophylaxis. Current recommendations for thromboprophylaxis must rely on consensus statements and expert opinions. The recently published German AWMF-Guideline 003/001 and the Green-top Guideline No. 37a from the Royal College of Obstetricians and Gynaecologists (RCOG) are discussed. The RCOG Guideline recommends antenatal thromboprophylaxis in women with previous VTE, high-risk thrombophilia or in the presence of ≥ 4 risk factors from the beginning of pregnancy, in women with 3 current risk factors from 28 weeks of gestation. After delivery women with intermediate risk should receive prophylactic LMWH for at least 10 days and women with high risk for 6 weeks postnatally. All women who have had an elective caesarean section and who have>1 additional risk factor should be given prophylactic NMH as well as all women who have had a caesarean section in labour or an emergency caesarean section. At the onset of labour, in case of any vaginal bleeding, prior to scheduled labour induction or at least 12 h before an elective caesarean section, antenatal LMWH prophylaxis should be discontinued. LMWH prophylaxis can be continued 4-6 h after vaginal delivery and 6-12 h after caesarean delivery when women do not have an increased risk of haemorrhage. Current guidelines recommend weight-based LMWH.


Assuntos
Anticoagulantes/administração & dosagem , Fibrinolíticos/administração & dosagem , Obstetrícia/normas , Guias de Prática Clínica como Assunto , Complicações Cardiovasculares na Gravidez/prevenção & controle , Tromboembolia Venosa/prevenção & controle , Medicina Baseada em Evidências , Feminino , Alemanha , Heparina de Baixo Peso Molecular/administração & dosagem , Humanos , Gravidez , Complicações Cardiovasculares na Gravidez/diagnóstico , Complicações Cardiovasculares na Gravidez/tratamento farmacológico , Resultado do Tratamento , Reino Unido , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/tratamento farmacológico
2.
J Med Life ; 8(3): 291-6, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26351529

RESUMO

RATIONALE: To elucidate the prepubertal risk factors associated with the development of Polycystic Ovary Syndrome (PCOS) and determine the special clinical manifestations of the syndrome in this transitional time of a woman's life. OBJECTIVE: To propose therapeutic targets and regimens, not only to prevent the long-term complications of the syndrome, but also to improve the self-esteem of a young girl who matures into womanhood. METHODS AND RESULTS: A systematic review of literature was performed through electronic database searches (Pubmed, Medline and Embase). Studies published in English-language, peer-reviewed journals from 1996 to 2013 were included. The selected studies focused on the risk factors, the unique features and treatment options of the PCOS in puberty. The pathogenesis of the PCOS was hypothesized to be based on interactions between genetic and certain environmental factors. The diagnosis was usually difficult in young girls. The syndrome was related to a greater risk of future infertility, type II diabetes mellitus, the metabolic syndrome and cardiovascular disease. Early treatment was crucial to prevent the long-term complications of the syndrome, especially infertility and cardiovascular disease. DISCUSSION: The recognition of the early signs of PCOS during or even before adolescence is of great importance. It is essential to establish the correct diagnosis for PCOS and rule out other causes of androgen excess in young women with hyperandrogenism. The type of treatment applied should be considered on an individual basis. ABBREVIATIONS: PCOS = Polycystic Ovary Syndrome.


Assuntos
Síndrome do Ovário Policístico/patologia , Adolescente , Diagnóstico Diferencial , Diagnóstico por Imagem , Feminino , Humanos , Síndrome do Ovário Policístico/diagnóstico , Síndrome do Ovário Policístico/terapia , Puberdade , Fatores de Risco
5.
Hamostaseologie ; 27(3): 177-84, 2007 Aug.
Artigo em Alemão | MEDLINE | ID: mdl-17694224

RESUMO

The findings of a large prospective study designed to identify primary and/or secondary haemostatic disorders before surgical interventions are presented. A total of 5649 unselected adult patients were enrolled to identify impaired haemostasis before surgical interventions. Each patient was asked to answer a standardized questionnaire concerning bleeding history. Activated partial thromboplastin time (aPTT), prothrombin time (PT), and platelet counts (PC) including PFA-100 (platelet function analyzer): collagen-epinephrine (C/E), and collagen-ADP (C/ADP) were routinely done in all patients. Additional tests, bleeding time (BT), von Willebrand factor (VWF:Ag, VWF:Rcof) and a further haemostaseological diagnostic was performed only in patients with a positive bleeding history and/or evidence of impaired haemostasis; e.g., drug ingestion. The bleeding history was negative in 5021 patients (88.8%) but positive in the remaining 628 (11.2%). Impaired haemostasis could be verified only in 256 (40.8%) of these patients. The vast majority was identified with PFA-100: C/E (n = 250; 97.7%). The sensitivity of the PFA-100: collagen-epinephrine was the highest (90.8%) in comparison to the other screening tests (BT, aPTT, PT, VWF : Ag). The positive predictive value (to detection of impaired haemostasis) of the PFA-100: collagen-epinephrine with the standardized questionnaire was high (82%), but the negative predictive value was higher (93%). The use of a standardized questionnaire and, if indicated, the PFA-100: C/E and/or other specific tests not only ensure the detection of impaired haemostasis in almost every case but also a significant reduction of the costs. Based on these data, national regards are formulated or under construction.


Assuntos
Transtornos Hemostáticos/diagnóstico , Cuidados Pré-Operatórios , Difosfato de Adenosina/farmacologia , Tempo de Sangramento , Plaquetas/efeitos dos fármacos , Plaquetas/fisiologia , Colágeno/farmacologia , Epinefrina/farmacologia , Transtornos Hemostáticos/sangue , Humanos , Ativação Plaquetária , Contagem de Plaquetas , Estudos Prospectivos , Tempo de Protrombina , Inquéritos e Questionários
7.
Thromb Res ; 108(5-6): 291-6, 2002 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-12676188

RESUMO

The influence of unfractionated (Heparin-Natrium) and low-molecular heparin (Fragmin(R)) on platelet activation in whole blood was investigated by FACS analysis in vitro using antibodies against glycoprotein (gp) IIb/IIIa (CD 41), GMP 140 (CD 62P), gp 53 (CD 63) and fibrinogen. Samples were also labeled with anti-gp Ib (CD 42b). Neither unfractionated heparin (UFH) nor low molecular weight heparin (LMWH) led to significant (i.e., p<0.05) changes in fluorescence intensities of platelets labeled with anti-gp IIb/IIIa or anti-gp 53. Significant platelet activation due to unfractionated heparin could be observed by labeling with anti-GMP 140 (UFH: p=0.009; LMWH: p=0.16). The proportion of platelets with surface-bound fibrinogen was significantly increased (UFH: p=0.00006; LMWH: p=0.008). After incubation with heparins, activation ability of platelets by adenosine diphosphate (ADP) was significantly increased. The potentiating action of unfractionated heparin was larger. Therefore, flow cytometric results of platelet activation in patients receiving heparin should be interpreted carefully.


Assuntos
Sangue , Citometria de Fluxo , Heparina/farmacologia , Ativação Plaquetária/efeitos dos fármacos , Difosfato de Adenosina/farmacologia , Adulto , Fibrinogênio/análise , Fibrinogênio/efeitos dos fármacos , Heparina de Baixo Peso Molecular/farmacologia , Humanos , Selectina-P/análise , Selectina-P/efeitos dos fármacos
8.
Clin Appl Thromb Hemost ; 7(4): 281-5, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11697709

RESUMO

Several therapeutic regimens have been proposed for women with recurrent spontaneous abortion (RSA) and antiphospholipid antibodies (APA). Conflicting results have been reported about women with history of RSA, positive APA, and failure of standard therapy. To evaluate the use of intravenous immunoglobulin in RSA patients with APA and history of treatment failure, we initiated a study with standard therapy (aspirin and low-molecular-weight heparin) and intravenous immunoglobulin. We used an enzyme-linked immunosorbent assay (ELISA) test to screen IgG and IgM anticardiolipin antibodies, and a diluted Russel viper venom time assay for the lupus anticoagulant activity. Altogether, 66 pregnant women with positive APAs at the first visit could be included. Patients with hereditable thrombophilic factors were excluded. After confirmation of the pregnancy, women received a basis immunization of 0.3 g/kg immunoglobulin in a 4-week cycle until the 28th to 32nd week of gestation. All patients received 100 mg/d aspirin and 3,000 anti-Xa U/d certoparin. Among the 66 pregnant women, 17 were persistently autoantibody positive (25.8%), of whom 11 (16.7%) were ACA positive alone, 2 (3%) were lupus anticoagulant positive, and 4 (6.4%) had both antibody types. A total of 49 patients had positive APAs at the initial test, but were negative for ACA and lupus anticoagulant at the second test administered approximately 5 weeks after the start of therapy. We described this group in our following observation as "antibody negative." Sixteen of the 17 autoantibody-positive patients (94.1%) were delivered of live infants compared with 40 patients (81.6%) in the antibody-negative group (odds ratio [OR]: 1.2; 95% CI: 0.98 to 1.4). The overall miscarriage rate was 12.1% and the fetal loss rate was 15.2%. Four patients (25%) in the antibody-positive group developed symptoms of preeclampsia and fetal growth retardation compared with four patients (9.8%) in the antibody-negative group. In conclusion, we see a reduction of the fetal loss rate in patients with RSA and positive APA (5.8%) compared with APA-negative (18.4%) women with the same therapy (OR: 0.3; 95% CI: 0.04 to 2.3).


Assuntos
Aborto Habitual/tratamento farmacológico , Anticorpos Antifosfolipídeos/fisiologia , Resultado da Gravidez , Aborto Habitual/prevenção & controle , Adulto , Anticorpos Anticardiolipina/sangue , Anticorpos Antifosfolipídeos/sangue , Feminino , Morte Fetal/prevenção & controle , Humanos , Imunoglobulinas Intravenosas/administração & dosagem , Imunoglobulinas Intravenosas/farmacologia , Inibidor de Coagulação do Lúpus/sangue , Razão de Chances , Gravidez
10.
Gynecol Oncol ; 82(3): 523-31, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11520150

RESUMO

OBJECTIVE: The present study was planned to measure preoperative levels of soluble urokinase plasminogen activator receptor (suPAR) in plasma from patients with gynecological diseases, and to test for a relationship to clinical and biochemical patient characteristics. METHODS: Using a specific and sensitive kinetic ELISA, suPAR levels were determined in preoperative citrate plasma samples from 53 ovarian, 34 endometrial, and 30 cervical cancer patients, 17 patients with benign ovarian tumors, and 28 patients with benign endometrial diseases. In addition, suPAR was measured in citrate samples from 31 female blood donors. RESULTS: suPAR was measurable in all samples. No significant difference was found between plasma suPAR in the blood donors and the patients with benign diseases (P = 0.58). The groups of cancer patients had suPAR levels that were significantly higher than those found in the blood donors (P < 0.0001, P < 0.0001, and P = 0.001 for patients with ovarian, endometrial, and cervical cancer, respectively). In all groups of cancer patients a trend toward increasing suPAR levels with increasing FIGO stage was noted (P = 0.0003, P = 0.02, and P = 0.01 for patients with ovarian, endometrial, and cervical cancer, respectively). Using the median suPAR level to dichotomize the ovarian cancer patients, FIGO stages I-III, a significantly increased risk of progression/relapse was found for patients with high suPAR levels (Hazard ratio (HR) = 3.1, 95% CI: 1.1-8.8, P = 0.03). A multivariate analysis was performed, including suPAR, FIGO stage, and CA-125. Only FIGO stage III compared with FIGO stage I was significant (HR = 15, 95% CI: 1.8-129, P = 0.01). Survival analyses were not performed in the endometrial or cervical cancer patients due to few progressions/relapses during the follow-up period. CONCLUSION: This study concludes that patients with gynecological cancers have elevated plasma suPAR levels as compared with healthy female blood donors and patients with benign gynecological diseases. In addition, high preoperative plasma levels of suPAR are significantly associated with poor outcome of ovarian cancer patients. However, additional studies are needed to further validate the clinical usefulness of plasma suPAR measurements in the management of ovarian cancer patients.


Assuntos
Neoplasias do Endométrio/sangue , Neoplasias Ovarianas/sangue , Receptores de Superfície Celular/sangue , Neoplasias do Colo do Útero/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígeno Ca-125/sangue , Intervalo Livre de Doença , Neoplasias do Endométrio/imunologia , Neoplasias do Endométrio/patologia , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Pessoa de Meia-Idade , Análise Multivariada , Estadiamento de Neoplasias , Doenças Ovarianas/sangue , Doenças Ovarianas/patologia , Neoplasias Ovarianas/imunologia , Neoplasias Ovarianas/patologia , Cuidados Pré-Operatórios , Receptores de Ativador de Plasminogênio Tipo Uroquinase , Sensibilidade e Especificidade , Solubilidade , Neoplasias do Colo do Útero/imunologia , Neoplasias do Colo do Útero/patologia , Hemorragia Uterina/sangue , Hemorragia Uterina/patologia
11.
Clin Appl Thromb Hemost ; 7(1): 29-32, 2001 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11190901

RESUMO

Preeclampsia is associated with an increased platelet activation; however, there are few studies concerning platelet activation of the newborn. The aim of our study was to compare platelet activation in newborns of preeclamptic mothers to newborns of healthy mothers by using whole blood flow cytometry. Blood samples were obtained from 20 newborns (10 healthy controls, 10 cases of preeclampsia/HELLP [hemolysis, elevated liver enzymes, and low platelet count] syndrome) during cesarean section. Antibodies against the following antigens were used as markers for platelet activation: CD 41, CD62P, CD 63, and platelet-bound fibrinogen. In addition to the basal platelet activation, the ability of platelets to undergo activation as a result of in vitro incubation with a weak agonist (adenosine diphosphate) was evaluated. A significant difference between the groups concerning basal platelet activation could only be seen for platelet-bound fibrinogen; the control group showed a higher extent of platelet activation (16.6 +/- 11.3 vs. 6.1 +/- 4.9; p = 0.03). Incubation with adenosine diphosphate in the control group resulted in minor increases of platelet activation, which was significant only for platelet-bound fibrinogen (16.6 +/- 11.3 vs. 42.5 +/- 22.1; p = 0.02). However, the preeclamptic group showed significantly increased levels of platelet activation for all used markers after in vitro activation (CD 41: 115.6 +/- 18.2 vs. 163.2 +/- 29.6; p = 0.002; CD62P: 2.4 +/- 0.4 vs. 3.9 +/- 0.3; p < 0.001; CD 63: 2.7 +/- 0.5 vs. 3.7 +/- 0.6; p = 0.002; platelet-bound fibrinogen: 6.1 +/- 4.9 vs. 55.1 +/- 9.1; p < 0.001). Preeclampsia or HELLP syndrome is therefore associated with an increased susceptibility to neonatal platelets, even against weak activators such as adenosine diphosphate. Whether this results from peculiarities in the fetal vascular environment or maternal influences is yet uncertain.


Assuntos
Recém-Nascido/sangue , Ativação Plaquetária , Pré-Eclâmpsia/sangue , Difosfato de Adenosina/farmacologia , Antígenos CD/sangue , Biomarcadores/sangue , Feminino , Fibrinogênio/metabolismo , Citometria de Fluxo , Síndrome HELLP/sangue , Síndrome HELLP/etiologia , Humanos , Masculino , Ativação Plaquetária/efeitos dos fármacos , Ativação Plaquetária/fisiologia , Pré-Eclâmpsia/etiologia , Gravidez
12.
Clin Hemorheol Microcirc ; 25(3-4): 83-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11847411

RESUMO

We examined the hemodynamic and hemorheological effects of intravenous volume expansion in women with pre-eclampsia. 20 untreated women with moderate pre-eclampsia were randomized to receive a 500 ml infusion over 4 h of either hydroxyethylstarch (HAES steril 10%, HES) or NaCl 0.9% solution. After completion of the infusion trial all patients received oral antihypertensive drugs, bed rest and free sodium and water intake. The hemodynamic responses were measured by impedance cardiography. Hemorheological parameters and blood pressure were measured before and after (24 h later) infusion. The HES infusion but not NaCl leads to a significant reduction of hematocrit and erythrocyte aggregation. In addition to that there was a nonsignificant increase of the cardiac index in the HES-group but no changes in the heart rate. Intravenous volume expansion in women with pre-eclampsia with a long acting colloid like hydroxyethylstarch is associated with a significant influence on the flow properties (hematocrit and erythrocyte aggregation) of blood.


Assuntos
Hidratação , Hemodinâmica/efeitos dos fármacos , Hemorreologia/efeitos dos fármacos , Derivados de Hidroxietil Amido/uso terapêutico , Substitutos do Plasma/uso terapêutico , Pré-Eclâmpsia/terapia , Adolescente , Adulto , Viscosidade Sanguínea/efeitos dos fármacos , Coloides/farmacologia , Coloides/uso terapêutico , Soluções Cristaloides , Agregação Eritrocítica/efeitos dos fármacos , Feminino , Fibrinogênio/análise , Hematócrito , Humanos , Derivados de Hidroxietil Amido/farmacologia , Soluções Isotônicas , Substitutos do Plasma/farmacologia , Gravidez , Reprodutibilidade dos Testes , Cloreto de Sódio/farmacologia , Cloreto de Sódio/uso terapêutico , Resultado do Tratamento
13.
Hematol Oncol Clin North Am ; 14(5): 1133-50, ix, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11005038

RESUMO

Venous thromboembolism remains a major cause of morbidity and mortality associated with pregnancy and puerperium. Specific risk factors for this disorder can be identified before or during pregnancy and delivery. The heritable defects believed to be associated with venous thrombosis are factor V Leiden mutation; elevated antiphospholipid antibodies; and deficiencies of antithrombin, protein C, and protein S. Women with a history of thromboembolism and thrombophilia should receive antenatal and postpartum thrombosis prophylaxis.


Assuntos
Fibrinolíticos/uso terapêutico , Complicações Cardiovasculares na Gravidez/prevenção & controle , Trombose/prevenção & controle , Adulto , Feminino , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Idade Materna , Gravidez , Gravidez de Alto Risco , Fatores de Risco , Trombose Venosa/etiologia , Trombose Venosa/prevenção & controle
14.
Hematol Oncol Clin North Am ; 14(5): 1151-69, ix, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11005039

RESUMO

The European Consensus Conference has assessed the risk for thrombotic complications for most women undergoing gynecologic surgery and found it to be moderate. Nonetheless, it is important to analyze a patient's individual risk before surgery so that appropriate thrombosis prophylaxis can be given if increased risk is determined. Malignancy accounts for most thrombotic complications among gynecologic patients. Patients with known malignancies should receive prophylaxis during surgery, and some patients with breast cancer should receive prophylaxis during chemotherapy. Heparin, and low-molecular-weight heparin in particular, may favorably influence the outcome of cancer in some patients and treatment with these agents is currently under investigation in a number of trials as a new approach to anticancer therapy.


Assuntos
Fibrinolíticos/uso terapêutico , Neoplasias dos Genitais Femininos/terapia , Procedimentos Cirúrgicos em Ginecologia , Trombose Venosa/prevenção & controle , Antineoplásicos/efeitos adversos , Feminino , Neoplasias dos Genitais Femininos/tratamento farmacológico , Neoplasias dos Genitais Femininos/radioterapia , Neoplasias dos Genitais Femininos/cirurgia , Hemorragia/induzido quimicamente , Heparina/efeitos adversos , Heparina/uso terapêutico , Humanos , Complicações Intraoperatórias , Fatores de Risco , Trombose Venosa/etiologia
15.
Clin Hemorheol Microcirc ; 22(2): 107-30, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10831062

RESUMO

In cancer patients impaired blood rheology in the presence of coagulation activation may reduce blood flow in the vascular microcirculation that favors thrombosis but may also support tumor progression and metastasis. In 451 patients with gynecological cancer and 177 patients with corresponding benign tumor disease preoperatively, during adjuvant treatment, when venous thrombosis (VT) or cancer progression was diagnosed hematocrit (micro centrifuge), hemoglobin, leukocytes, platelets (Coulter Counter); red blood cell (RBC) aggregation (aggr.) during stasis and low shear conditions (MA 1, Myrenne), plasma viscosity (viscosimeter KSPV 1 Fresenius), and fibrinogen (Multifibren Behring Dade) were investigated. One hundred and twelve healthy women served as controls. Preoperatively, mean plasma viscosity (pv) was significantly higher in cancer patients as compared to patients with the corresponding benign tumor disease (breast cancer: n = 261; pv = 1.32 vs. 1.27 mPa s; p = 0.023; ovarian cancer: n = 68; pv = 1.39 vs. 1.31 mPa s; p < 0.001; endometrial cancer: n = 70; pv = 1.37 vs. 1.25 mPa s; p < 0.001; cervical cancer: n = 52; pv = 1.33 vs. 1.26 mPa s; p = 0.004). RBC aggr. was significantly lower in controls compared to the preoperative values in cancer patients but mean (median) values (RBC aggr. stasis < 21) were within the normal range in all. Preoperatively, plasma viscosity was a significant risk factor for the overall survival in ovarian cancer patients (p = 0.02) and for subsequent thrombosis in ovarian (p = 0.02) and cervical cancer patients (p = 0.007). In the multivariate analysis plasma viscosity was an independent prognostic marker for the overall survival of breast cancer patients (r = 99.45; 95% CI: 7.32-980.2; p < 0.0001). An optimized preoperative cut-off value above 1.40 mPa s (Log-Rank-test) was significantly associated with poor outcome in the Kaplan-Mayer survival estimates, even in node-negative breast cancer. In gynecologic cancer patients the combination of an increase in RBC aggregation and plasma viscosity impairs blood-flow-properties and may induce hypoxia in the microcirculation that favors thrombosis, settlement of tumor-cells and thus metastasis. Improvement of blood fluidity and thus oxygen transfer in the tumor-vascular-microcirculation may increase susceptibility of systemic anti-cancer therapy.


Assuntos
Neoplasias dos Genitais Femininos/sangue , Hemorreologia , Trombofilia/etiologia , Trombose Venosa/epidemiologia , Adulto , Idoso , Antineoplásicos/farmacocinética , Contagem de Células Sanguíneas , Viscosidade Sanguínea , Neoplasias da Mama/sangue , Neoplasias da Mama/complicações , Neoplasias da Mama/mortalidade , Neoplasias da Mama/terapia , Carcinoma/sangue , Carcinoma/complicações , Carcinoma/mortalidade , Carcinoma/terapia , Hipóxia Celular , Estudos de Coortes , Progressão da Doença , Agregação Eritrocítica , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinogênio/análise , Seguimentos , Neoplasias dos Genitais Femininos/complicações , Neoplasias dos Genitais Femininos/mortalidade , Neoplasias dos Genitais Femininos/terapia , Alemanha/epidemiologia , Hematócrito , Humanos , Tábuas de Vida , Microcirculação , Pessoa de Meia-Idade , Metástase Neoplásica , Células Neoplásicas Circulantes , Neoplasias Ovarianas/sangue , Neoplasias Ovarianas/complicações , Neoplasias Ovarianas/mortalidade , Neoplasias Ovarianas/terapia , Estudos Prospectivos , Fatores de Risco , Análise de Sobrevida , Neoplasias do Colo do Útero/sangue , Neoplasias do Colo do Útero/complicações , Neoplasias do Colo do Útero/mortalidade , Neoplasias do Colo do Útero/terapia , Neoplasias Uterinas/sangue , Neoplasias Uterinas/complicações , Neoplasias Uterinas/mortalidade , Neoplasias Uterinas/terapia , Trombose Venosa/etiologia
16.
Int J Oncol ; 16(4): 815-24, 2000 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10717252

RESUMO

Recent studies suggest that low molecular weight heparin (LMW heparin) therapy in malignancy may improve cancer survival following surgical resection. We studied prospectively whether cancer mortality during follow-up in women with previously untreated breast, and pelvic cancer is reduced in those who randomly received LMW heparin (Certoparin) compared to patients given unfractionated heparin (UF heparin) for thrombosis prophylaxis during primary surgery. In a prospective, randomized, double-blind clinical trial, 160 patients received Certoparin and 164 UF heparin until post-operatively day 7. Survival estimations are based on the outcome data from a subset of 140 LMW heparin - and 147 UF heparin recipients. Long-term survival in the Certoparin group compared to the UF heparin group was significantly improved after 650 days (P=0. 0066) but not thereafter when analysis was performed on all cancer cell types combined. In the probability estimates survival benefit within this time was restricted to patients with pelvic cancer but was not observed in breast cancer. However, in breast cancer patients who received LMW heparin the impact of classical tumor prognostic markers was statistically significant after 1,050 days but not after 650 days. Thus, breast cancer patients with unfavorable prognosis seem to benefit in terms of survival advantage from LMW heparin within the 650 days after surgery. These results suggest that improvement in cancer survival can be achieved after even a short course of treatment with LMWH (compared to UFH) given for DVT prophylaxis in the post-operative period. An effect of UFH on disease outcome is not excluded. Further definitive trials of LMWH vs. placebo for cancer outcome (rather then DVT) using doses and schedules that may be more optimal are indicated.


Assuntos
Neoplasias da Mama/terapia , Heparina de Baixo Peso Molecular/uso terapêutico , Heparina/uso terapêutico , Neoplasias do Colo do Útero/terapia , Adulto , Idoso , Neoplasias da Mama/mortalidade , Método Duplo-Cego , Feminino , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Taxa de Sobrevida , Neoplasias do Colo do Útero/mortalidade
20.
Clin Appl Thromb Hemost ; 5(2): 92-104, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10725988

RESUMO

Thromboembolism is a severe and frequent problem in gynecologic malignancy. The average DVT incidence during chemotherapy of 5% might represent the lower range of incidence because < 55% of thrombotic complication manifest clinical signs. However, it seems likely that in addition to chemotherapy other risk factors such as menopausal status, BMI of patients, or type of preceding surgery must coincide before thrombosis manifests. While monitoring of patients using sophisticated coagulation tests did not identify patients' risk for DVT during chemotherapy, an evaluation of the coagulation status before initiating chemotherapy is recommended. Patients with a venous access device (e.g., indwelling central venous catheter or with port cart) are at a particularly high risk for DVT. This has to be considered when cytoreductive therapy is given. Thrombosis prophylaxis, orally or subcutaneously, should only be considered in a subpopulation of patients who offer a combination of the aforementioned risk factors. Thrombosis prevention trials during chemotherapy found a significant reduction of DVT in patients treated with anticoagulants.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias dos Genitais Femininos/sangue , Neoplasias dos Genitais Femininos/tratamento farmacológico , Trombose Venosa/sangue , Neoplasias da Mama/sangue , Neoplasias da Mama/complicações , Neoplasias da Mama/tratamento farmacológico , Feminino , Neoplasias dos Genitais Femininos/complicações , Humanos , Neoplasias Ovarianas/sangue , Neoplasias Ovarianas/complicações , Neoplasias Ovarianas/tratamento farmacológico , Trombose Venosa/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA